24th Nov 2021 12:05
24th November 2021
Result of AGM and Board Change
Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceutical and Services and Products company, held its Annual General Meeting ('AGM') today at which all resolutions were passed. Resolutions 1-13 were passed as Ordinary Resolutions and Resolutions 14 and 15 were passed as Special Resolutions.
A minority of shareholders opposed Resolutions 2 (Directors' Remuneration Report for year ended 30 June 2021), 7 (re-election of Anne Hyland), 8 (re-election of Alan Boyd), and 13 (authorise the Directors to allot shares pursuant to section 551). In accordance with the FRC Code of Corporate Governance the Board will be consulting with major shareholders in order to understand the reasons why votes of over 20% were cast against the resolutions, and an update on views received and actions taken will be published no later than six months after today's date. The vote for Resolution 2 was advisory only.
Full details of the poll results will be made available on Clinigen's website at www.clinigengroup.com.
As previously announced on August 3, Ian Nicholson has stepped down from the Board and Sharon Curran will take over as Chair of the Remuneration Committee with immediate effect.
Elmar Schnee, Chairman of Clinigen, said: "Ian has provided valuable guidance and support to the Clinigen Board since his appointment in 2012. We would like to thank him for his contribution and wish him well for the future."
- Ends -
Contact details
Clinigen Group plc | +44 (0) 1283 495010 |
Rob Fox, VP Investor Relations and Corporate Development | |
Numis Securities Limited - Nominated Adviser & Joint Broker | Tel: +44 (0) 20 7260 1000 |
James Black / Garry Levin / Freddie Barnfield |
|
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas | |
Consilium Strategic Communications Mary-Jane Elliott / Matthew Cole / Jessica Hodgson | Tel: +44 (0) 20 3709 5700 [email protected]
|
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.
Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.
For more information on Clinigen, please visit http://www.clinigen.com
Related Shares:
CLIN.L